8 ways for pharma to improve the way it uses Twitter

Twitter's health team offers advice on how pharma and healthcare companies can more effectively utilize 140 characters.

Healthcare marketers: Don't forget about the baby boomers

Baby boomers have taken to health tech with surprising ease, opening up a wealth of opportunities for marketers savvy enough to pursue them.

As immuno-oncology therapies evolve, so will the marketing

Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.

Five things for pharma marketers to know: Thursday, July 28, 2016

Five things for pharma marketers to know: Thursday, July 28, 2016

Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi's Adlyxin

Infographic: Type 2 diabetes, a country-by-country snapshot

Infographic: Type 2 diabetes, a country-by-country snapshot

Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.

W2O names Gillespie chief strategy officer of medtech practice

W2O names Gillespie chief strategy officer of medtech practice

She will be responsible for the medical device practice's strategy and operations across all W2O Group agencies.

Five things for pharma marketers to know: Wednesday, July 27, 2016

Five things for pharma marketers to know: Wednesday, July 27, 2016

IBM to help analyze data about the spread of Zika; Grassley to investigate Part D program; Lilly CEO to retire

Five things for pharma marketers to know: Tuesday, July 26, 2016

Five things for pharma marketers to know: Tuesday, July 26, 2016

Sales of Gilead's HCV drugs fall; the DNC policy platform criticized price gouging; Janssen partners with Bristol-Myers Squibb on Opdivo combo drug

Huntsworth Health revenue rose 18% in the first half of 2016

Huntsworth Health revenue rose 18% in the first half of 2016

Red, a Huntsworth agency, also counted Sanofi as a new client.

M Booth supports Leukemia & Lymphoma Society's Light the Night campaign

M Booth supports Leukemia & Lymphoma Society's Light the Night campaign

The nonprofit is dedicated to curing blood cancer.

GSK Consumer Healthcare to prioritize digital after agency review

GSK Consumer Healthcare to prioritize digital after agency review

Now that it has consolidated its global agency roster, GSK Consumer Healthcare aims to increase digital marketing efforts.

Five things for pharma marketers to know: Monday, July 25, 2016

Five things for pharma marketers to know: Monday, July 25, 2016

Darzalex may interfere with blood testing; Kaine scrutinized for ties to pharma; medical societies are in support of bill exempting CME reporting

CAR-T therapies: the future of cancer care, or an industry pipe dream?

CAR-T therapies: the future of cancer care, or an industry pipe dream?

While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.

Top 25 oncology products in 2015

Top 25 oncology products in 2015

Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.

Five things for pharma marketers to know: Friday, July 22, 2016

Five things for pharma marketers to know: Friday, July 22, 2016

Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals

Biogen ends Tecfidera DTC campaign, citing prescriptions

Biogen ends Tecfidera DTC campaign, citing prescriptions

The drugmaker had launched the campaign for the multiple sclerosis drug in 2015.

Five things for pharma marketers to know: Thursday, July 21, 2016

Five things for pharma marketers to know: Thursday, July 21, 2016

The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers

Avanir marketing chief on selling first-in-class therapies

Avanir marketing chief on selling first-in-class therapies

Avanir's success with Nuedexta sparked the attention of several suitors. In 2014 the company reached a deal to be sold to Otsuka Pharmaceutical for around $3.5 billion

Agency Spotlight


OPINION

Email Newsletters